Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Drug

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment

Fineline Cube Jul 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Company Drug

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388

Fineline Cube Jul 16, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Deals

Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System

Fineline Cube Jul 16, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...

Company Drug

AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial

Fineline Cube Jul 16, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...

Company Medical Device

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System

Fineline Cube Jul 16, 2025

Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced that it has received the marketing license...

Policy / Regulatory

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals

Fineline Cube Jul 16, 2025

China’s National Medical Products Administration (NMPA) has released the 94th batch of reference drugs for...

Company Deals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal

Fineline Cube Jul 16, 2025

US major Becton, Dickinson and Co., (BD) is set to merge its Biosciences & Diagnostic...

Company Deals

Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million

Fineline Cube Jul 16, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based...

Company Drug

Vigonvita’s Simenafil Receives NMPA Approval for Erectile Dysfunction Treatment

Fineline Cube Jul 16, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd., announced that it has received marketing approval from the...

Company Deals

Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development

Fineline Cube Jul 16, 2025

Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...

Company Deals

Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases

Fineline Cube Jul 16, 2025

Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB...

Company Drug

Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020

Fineline Cube Jul 15, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Deals

Ningbo Health Gene and Biofast Biotech Partner to Advance Genetic Testing for Hereditary Diseases

Fineline Cube Jul 15, 2025

Chinese firms Ningbo Health Gene Technologies Co., Ltd. and Biofast Biotechnology Co., Ltd. announced late...

Company Deals

Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion

Fineline Cube Jul 15, 2025

German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...

Company Medical Device

Peijia Medical Completes First Patient Implantation for MonarQ TTVR System in Global Clinical Study

Fineline Cube Jul 15, 2025

China-based Peijia Medical Ltd (HKG: 9996) announced the successful completion of the first patient implantation...

Company Deals

Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China

Fineline Cube Jul 15, 2025

Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has...

Company Drug

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527

Fineline Cube Jul 15, 2025

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) announced the initiation of the EXPrESSIVE Phase...

Company Drug

China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials

Fineline Cube Jul 15, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) announced that it has received clinical trial...

Policy / Regulatory

NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate

Fineline Cube Jul 15, 2025

The National Healthcare Security Administration (NHSA) this week released its national medical and healthcare development...

Company Drug

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data

Fineline Cube Jul 15, 2025

SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...

Posts pagination

1 … 90 91 92 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.